Stada Arzneimi Namen (STDAF) 54.0500 $STDAF
Research and Markets - Global Generic Drugs Market 2016 - Forecasts to 2020 with Teva, Sandoz, Allergan, Mylan, Sun Pharma & STADA Arzneimittel Dominating
PR Newswire Europe - Fri Jun 17, 10:10AM CDT
DUBLIN, June 17, 2016 /PRNewswire/ --
AGN: 249.61 (-3.41)
From Teva Pharmaceuticals to STADA Arzneimittel - Technavio Unveils Top Six Vendors in the Global Generic Drugs Market from 2016 to 2020
BusinessWire - Tue May 31, 11:00AM CDT
Technavio has announced the top six leading vendors in their recent global generic drugs market report. This research report also lists 49 other prominent vendors that are expected to impact the market during the forecast period.
Pharmaceutical Industry in China 2015
M2 - Tue Nov 03, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/364v6j/pharmaceutical) has announced the addition of the "Pharmaceutical Industry in China" report to their offering. This report Pharmaceutical Industry in China explores the Chinese Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the WTO accession of China and the impact it has had on the Chinese Pharmaceutical Industry, growth trends in the industry, competition in the industry, etc. The report also analyzes the Chinese pharmaceutical industry through three frameworks - a SWOT analysis, a PEST analysis, and a Porter's Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Chinese Pharmaceutical Industry, the role of the government in the industry, and investment opportunities in China's Pharmaceutical Industry. Complete with a comprehensive section on the clinical trials, market investment opportunities, an analysis of the fifteen leading players in the Chinese Pharmaceutical Industry, this latest research is a collection of all you need to know about China's Pharmaceutical Industry. Key Topics Covered: A. Executive Summary B. The Global Pharmaceutical Industry - A Brief Profile C. China Pharmaceutical Industry D. OTC Pharmaceuticals in China E. Generics Sector in China F. Market Trends & Growth Opportunities G. Regulatory Developments & Framework H. China Pharmaceutical Industry - SWOT Framework Analysis I. China Pharmaceutical Industry - PEST Framework Analysis J. China Pharmaceutical Industry - Porter's Five Forces Business Strategy Analysis K. Evolving Strategic Options for Chinese Companies L. Impact of Changing IP Laws on Product Level Access to Medicines in China M. Investment Options in China's Pharmaceutical Industry N. China's WTO Accession - Challenges & Opportunities O. Contract Research Services in China's Pharma Sector P. China's Pharmaceutical Industry - Future Perspective Q. Major Industry Players - AstraZeneca PLC - Bayer AG - Beijing Double-Crane Pharmaceutical (DCPC) - Beijing TongRenTang Co., Ltd. - GlaxoSmithKline Plc - Guilin Sanjin Pharmaceutical Co., Ltd. - Northeast Pharmaceutical Group (NEPG) - Novartis AG - Pfizer Inc - Roche Holding AG - Sanjiu Medical and Pharmaceutical Co. Ltd. (SMPCL) - Shanghai Pharmaceutical (Group) Co. Ltd (SPCL) - STADA Arzneimittel - Wuhan Grand Pharmaceutical - Yunnan Baiyao Group Co., Ltd. For more information visit http://www.researchandmarkets.com/research/36...maceutical
PFE: 34.98 (-0.17), AZN: 33.54 (-0.27), GSK: 44.17 (-0.22), NVS: 82.08 (-0.72)
Pediculosis (Head Lice Infestation) - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bdrs/pediculosis_head) has announced the addition of the "Pediculosis (Head Lice Infestation) Global Clinical Trials Review, H1, 2015" report to their offering. "Pediculosis (Head Lice Infestation) Global Clinical Trials Review, H1, 2015" provides data on the Pediculosis (Head Lice Infestation) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pediculosis (Head Lice Infestation). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pediculosis (Head Lice Infestation). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Pediculosis (Head Lice Infestation) Therapeutics Clinical Trials - Hatchtech Pty, Ltd - ParaPRO LLC - Stada Arzneimittel AG - Sun Pharmaceutical Industries Limited - Sanofi - Summers Laboratories Incorporated - Oystershell NV - Lybar, a.s. - EctoPharma Ltd. - Altman Biomedical Consulting Pty. Ltd - Mandacaru Foundation - Shiraz University of Medical Sciences - Assistance Publique Hopitaux De Marseille - Australian National University - Centers for Disease Control and Prevention - Hackensack University Medical Center - Royal Free London NHS Foundation Trust - South Florida Family Health And Research Centers - Tokyo University of Science For more information visit http://www.researchandmarkets.com/research/v2...losis_head
The Corporate Reputation of Pharma - The Global Patient Perspective in 2014
M2 - Thu Apr 16, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mv4rwp/the_corporate) has announced the addition of the "The Corporate Reputation of Pharma - The Patient Perspective in 2014 - Global Edition " report to their offering. The Corporate Reputation of Pharmafrom a Patient Perspective' is now in its fourth edition. This report contains the latest version (2014 results; published early 2015). For each annual Corporate Reputation report, the author surveys a large number of patient groups worldwideinternational, national, and regional, from across many different disease and healthcare specialties. 1,150 patient groups from 58 countries participated in the Corporate Reputation's 4th edition. About the questionnaire: The methodology for assessing pharma corporate reputation from a patient perspective was first established by PatientView in 2010 following consultations with pharma, medical-device companies, tradesbodies and patient groups. The resulting questionnaire combines the priorities of patient groups (which have a better understanding of pharma than individual patients) and industry on the topic of corporate reputation. The same questions on corporate reputation are posed to respondent patient groups every year (though each year's respondent patient groups are not necessarily the same as those of the previous year). The answers help define what patients require from pharma companies, while acknowledging what pharma itself thinks it is capable of delivering. Since the questions do not deviate, the Corporate Reputation of Pharma allows the performance of individual pharma companies (and the industry as a whole) to be compared year on yearwhich, in turn, helps define appropriate strategies for improvement. I was torn between ethical, transparency, and patient safety. But, ultimately, patient safety is the most important to me and to our organization Global, US-based patient group focusing on cancer and palliative care Key Topics Covered: - Introduction - Understanding The Results - Methodology - Appendices: - Reputation of Pharma in 2014 - Rankings of 37 Companies - Profiles of 37 Companies - Profile of Respondents Companies Mentioned - AbbVie - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer- Ingelheim - Bristol-Myers Squibb - Celgene - Eisai - Eli Lilly - GSK - Gilead - Gr?nenthal - Ipsen - Janssen - Lundbeck - Menarini - Merck & Co - Mylan - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shire - Stada Arzneimittel - Takeda - Teva - UCB For more information visit http://www.researchandmarkets.com/research/mv..._corporate
AGN: 249.61 (-3.41), BIIB: 313.94 (-0.55), NVO: 46.18 (-0.28), BAX: 48.59 (-0.44), MRK: 63.35 (-0.28), AMGN: 173.02 (+0.59), LLY: 80.22 (-0.34), BMY: 60.63 (-0.34), NVS: 82.08 (-0.72), CELGZ: 1.22 (+0.03)
Europe Biosimilars Market & Pipeline Insight 2014
M2 - Tue Oct 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bblsk8/europe) has announced the addition of the "Europe Biosimilars Market & Pipeline Insight" report to their offering. Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic incentives along with favorable pricing and reimbursement policies adopted across multiple markets in Europe. The current biosimilars market is highly fragmented in nature due to their accessibility in various therapeutic categories. The European biosimilars market is divided into various categories: Granulocyte-colony stimulating factor (G-CSF or GCSF), erythropoiesis-stimulating agents (ESAs) and somatropin biosimilars, Insulin, mAbs and follitropin. The present market fragmentation is driven by the availability of particular biosimilar products which were introduced over a decade ago. These products created niche among them and resulted in inclination toward a particular segments over a period of time. One of the most promising factors responsible for the development of biosimilars market is the patent expiration of reference drugs. The European biosimilars market is experiencing tremendous growth as blockbuster biologic drugs are going off-patent. The entry of new biosimilars due to patent expiry into various therapeutic indications has created a new category for the biosimilars. For instance, Ely Lily and Boehringer Ingelheim have already got marketing authorization of their biosimilar insulin in June'2014 even as the current diabetes drug (Lantus) marketed by Sanofi will go off patent in February'2015. The competitive pricing and reimbursement policies adopted by country specific regulators are also promoting the introduction of biosimilars in European market. The newly introduced biosimilars are approximately 20-30% cheaper and hence results in high level of acceptability among patients and physicians in comparison to originator molecule. The benefits of using the biosimilars include reimbursement provided by many governments which further decreases the financial burden from the patients as result of which they do not revert to originator molecules. Europe Biosimilars Market & Pipeline Insight Report Highlights: - Biosimilars Market Overview & Trend Analysis by Country - Biosimilars Introduction Timeline in Europe - Biosimilars Development & Market Authorization Guidelines - Biosimilars Clinical Pipeline by Phase, Indication, Company & Country - Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country - Europe Biosimilars Pipeline: 93 Biosimilars - Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine) Key Topics Covered: 1. Europe Biosimilars Market Overview 2. Europe Biosimilars Market Trend Analysis by Country 3. Biosimilars Introduction Timeline in Europe 4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario 5. Europe Biosimilars Market Dynamics 6. Future Prospectus of Biosimilars in Europe 7. Regulatory & Approval Authorities: EMA & CHMP 8. Biosimilars Development & Market Authorization Guidelines 9. Europe Biosimilars Clinical Pipeline by Phase, Indication, Company & Country 10. Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country 11. No Development Reported in Biosimilars Clinical Pipeline 12. Competitive Landscape - Apotex - Celltrion Healthcare - Finox Biotech - Hexal - Hospira - Medice Arzneimittel P?tter - Sandoz - Stada Arzneimittel - Teva Pharma For more information visit http://www.researchandmarkets.com/research/bblsk8/europe
Research and Markets - Global Generic Drugs Market 2016 - Forecasts to 2020 with Teva, Sandoz, Allergan, Mylan, Sun Pharma & STADA Arzneimittel Dominating
PR Newswire Europe - Fri Jun 17, 10:10AM CDT
DUBLIN, June 17, 2016 /PRNewswire/ --
AGN: 249.61 (-3.41)
From Teva Pharmaceuticals to STADA Arzneimittel - Technavio Unveils Top Six Vendors in the Global Generic Drugs Market from 2016 to 2020
BusinessWire - Tue May 31, 11:00AM CDT
Technavio has announced the top six leading vendors in their recent global generic drugs market report. This research report also lists 49 other prominent vendors that are expected to impact the market during the forecast period.
Pharmaceutical Industry in China 2015
M2 - Tue Nov 03, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/364v6j/pharmaceutical) has announced the addition of the "Pharmaceutical Industry in China" report to their offering. This report Pharmaceutical Industry in China explores the Chinese Pharmaceutical Industry landscape from the basics to the issues facing the industry today. The report delves in to the WTO accession of China and the impact it has had on the Chinese Pharmaceutical Industry, growth trends in the industry, competition in the industry, etc. The report also analyzes the Chinese pharmaceutical industry through three frameworks - a SWOT analysis, a PEST analysis, and a Porter's Five Forces Business Strategy analysis. The report also looks at strategies for market entry, the role of R&D in the Chinese Pharmaceutical Industry, the role of the government in the industry, and investment opportunities in China's Pharmaceutical Industry. Complete with a comprehensive section on the clinical trials, market investment opportunities, an analysis of the fifteen leading players in the Chinese Pharmaceutical Industry, this latest research is a collection of all you need to know about China's Pharmaceutical Industry. Key Topics Covered: A. Executive Summary B. The Global Pharmaceutical Industry - A Brief Profile C. China Pharmaceutical Industry D. OTC Pharmaceuticals in China E. Generics Sector in China F. Market Trends & Growth Opportunities G. Regulatory Developments & Framework H. China Pharmaceutical Industry - SWOT Framework Analysis I. China Pharmaceutical Industry - PEST Framework Analysis J. China Pharmaceutical Industry - Porter's Five Forces Business Strategy Analysis K. Evolving Strategic Options for Chinese Companies L. Impact of Changing IP Laws on Product Level Access to Medicines in China M. Investment Options in China's Pharmaceutical Industry N. China's WTO Accession - Challenges & Opportunities O. Contract Research Services in China's Pharma Sector P. China's Pharmaceutical Industry - Future Perspective Q. Major Industry Players - AstraZeneca PLC - Bayer AG - Beijing Double-Crane Pharmaceutical (DCPC) - Beijing TongRenTang Co., Ltd. - GlaxoSmithKline Plc - Guilin Sanjin Pharmaceutical Co., Ltd. - Northeast Pharmaceutical Group (NEPG) - Novartis AG - Pfizer Inc - Roche Holding AG - Sanjiu Medical and Pharmaceutical Co. Ltd. (SMPCL) - Shanghai Pharmaceutical (Group) Co. Ltd (SPCL) - STADA Arzneimittel - Wuhan Grand Pharmaceutical - Yunnan Baiyao Group Co., Ltd. For more information visit http://www.researchandmarkets.com/research/36...maceutical
PFE: 34.98 (-0.17), AZN: 33.54 (-0.27), GSK: 44.17 (-0.22), NVS: 82.08 (-0.72)
Pediculosis (Head Lice Infestation) - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bdrs/pediculosis_head) has announced the addition of the "Pediculosis (Head Lice Infestation) Global Clinical Trials Review, H1, 2015" report to their offering. "Pediculosis (Head Lice Infestation) Global Clinical Trials Review, H1, 2015" provides data on the Pediculosis (Head Lice Infestation) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pediculosis (Head Lice Infestation). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pediculosis (Head Lice Infestation). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Pediculosis (Head Lice Infestation) Therapeutics Clinical Trials - Hatchtech Pty, Ltd - ParaPRO LLC - Stada Arzneimittel AG - Sun Pharmaceutical Industries Limited - Sanofi - Summers Laboratories Incorporated - Oystershell NV - Lybar, a.s. - EctoPharma Ltd. - Altman Biomedical Consulting Pty. Ltd - Mandacaru Foundation - Shiraz University of Medical Sciences - Assistance Publique Hopitaux De Marseille - Australian National University - Centers for Disease Control and Prevention - Hackensack University Medical Center - Royal Free London NHS Foundation Trust - South Florida Family Health And Research Centers - Tokyo University of Science For more information visit http://www.researchandmarkets.com/research/v2...losis_head
The Corporate Reputation of Pharma - The Global Patient Perspective in 2014
M2 - Thu Apr 16, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mv4rwp/the_corporate) has announced the addition of the "The Corporate Reputation of Pharma - The Patient Perspective in 2014 - Global Edition " report to their offering. The Corporate Reputation of Pharmafrom a Patient Perspective' is now in its fourth edition. This report contains the latest version (2014 results; published early 2015). For each annual Corporate Reputation report, the author surveys a large number of patient groups worldwideinternational, national, and regional, from across many different disease and healthcare specialties. 1,150 patient groups from 58 countries participated in the Corporate Reputation's 4th edition. About the questionnaire: The methodology for assessing pharma corporate reputation from a patient perspective was first established by PatientView in 2010 following consultations with pharma, medical-device companies, tradesbodies and patient groups. The resulting questionnaire combines the priorities of patient groups (which have a better understanding of pharma than individual patients) and industry on the topic of corporate reputation. The same questions on corporate reputation are posed to respondent patient groups every year (though each year's respondent patient groups are not necessarily the same as those of the previous year). The answers help define what patients require from pharma companies, while acknowledging what pharma itself thinks it is capable of delivering. Since the questions do not deviate, the Corporate Reputation of Pharma allows the performance of individual pharma companies (and the industry as a whole) to be compared year on yearwhich, in turn, helps define appropriate strategies for improvement. I was torn between ethical, transparency, and patient safety. But, ultimately, patient safety is the most important to me and to our organization Global, US-based patient group focusing on cancer and palliative care Key Topics Covered: - Introduction - Understanding The Results - Methodology - Appendices: - Reputation of Pharma in 2014 - Rankings of 37 Companies - Profiles of 37 Companies - Profile of Respondents Companies Mentioned - AbbVie - Actavis - Allergan - Amgen - Astellas - AstraZeneca - Baxter International - Bayer - Biogen Idec - Boehringer- Ingelheim - Bristol-Myers Squibb - Celgene - Eisai - Eli Lilly - GSK - Gilead - Gr?nenthal - Ipsen - Janssen - Lundbeck - Menarini - Merck & Co - Mylan - Novartis - Novo Nordisk - Otsuka - Pfizer - Roche - Sanofi - Servier - Shire - Stada Arzneimittel - Takeda - Teva - UCB For more information visit http://www.researchandmarkets.com/research/mv..._corporate
AGN: 249.61 (-3.41), BIIB: 313.94 (-0.55), NVO: 46.18 (-0.28), BAX: 48.59 (-0.44), MRK: 63.35 (-0.28), AMGN: 173.02 (+0.59), LLY: 80.22 (-0.34), BMY: 60.63 (-0.34), NVS: 82.08 (-0.72), CELGZ: 1.22 (+0.03)
Europe Biosimilars Market & Pipeline Insight 2014
M2 - Tue Oct 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bblsk8/europe) has announced the addition of the "Europe Biosimilars Market & Pipeline Insight" report to their offering. Biosimilars have emerged as one of the most promising segment of the European pharmaceutical industry in recent years. The biosimilars segment has been experiencing a steady growth driven by patent expiration of blockbuster drugs, amenable regulatory framework, economic incentives along with favorable pricing and reimbursement policies adopted across multiple markets in Europe. The current biosimilars market is highly fragmented in nature due to their accessibility in various therapeutic categories. The European biosimilars market is divided into various categories: Granulocyte-colony stimulating factor (G-CSF or GCSF), erythropoiesis-stimulating agents (ESAs) and somatropin biosimilars, Insulin, mAbs and follitropin. The present market fragmentation is driven by the availability of particular biosimilar products which were introduced over a decade ago. These products created niche among them and resulted in inclination toward a particular segments over a period of time. One of the most promising factors responsible for the development of biosimilars market is the patent expiration of reference drugs. The European biosimilars market is experiencing tremendous growth as blockbuster biologic drugs are going off-patent. The entry of new biosimilars due to patent expiry into various therapeutic indications has created a new category for the biosimilars. For instance, Ely Lily and Boehringer Ingelheim have already got marketing authorization of their biosimilar insulin in June'2014 even as the current diabetes drug (Lantus) marketed by Sanofi will go off patent in February'2015. The competitive pricing and reimbursement policies adopted by country specific regulators are also promoting the introduction of biosimilars in European market. The newly introduced biosimilars are approximately 20-30% cheaper and hence results in high level of acceptability among patients and physicians in comparison to originator molecule. The benefits of using the biosimilars include reimbursement provided by many governments which further decreases the financial burden from the patients as result of which they do not revert to originator molecules. Europe Biosimilars Market & Pipeline Insight Report Highlights: - Biosimilars Market Overview & Trend Analysis by Country - Biosimilars Introduction Timeline in Europe - Biosimilars Development & Market Authorization Guidelines - Biosimilars Clinical Pipeline by Phase, Indication, Company & Country - Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country - Europe Biosimilars Pipeline: 93 Biosimilars - Marketed Biosimilars: 18 Biosimilars (17 Approved by EMA & 1 in Ukraine) Key Topics Covered: 1. Europe Biosimilars Market Overview 2. Europe Biosimilars Market Trend Analysis by Country 3. Biosimilars Introduction Timeline in Europe 4. Europe Biosimilars Risk Management Planning & Safety Regulation Scenario 5. Europe Biosimilars Market Dynamics 6. Future Prospectus of Biosimilars in Europe 7. Regulatory & Approval Authorities: EMA & CHMP 8. Biosimilars Development & Market Authorization Guidelines 9. Europe Biosimilars Clinical Pipeline by Phase, Indication, Company & Country 10. Marketed Biosimilars Clinical Insight by Phase, Indication, Company & Country 11. No Development Reported in Biosimilars Clinical Pipeline 12. Competitive Landscape - Apotex - Celltrion Healthcare - Finox Biotech - Hexal - Hospira - Medice Arzneimittel P?tter - Sandoz - Stada Arzneimittel - Teva Pharma For more information visit http://www.researchandmarkets.com/research/bblsk8/europe
